10x Genomics, Inc.
$61.54
The Read: After meeting earnings expectations and receiving positive guidance in early 2026, TXG saw a bull run fueled by strategic partnerships and product launches, but a sharp sell-off followed strong Q2 results due to overbought positioning, only to rebound further with ASCO-driven momentum and a strategic acquisition that solidified its market position.
TXG
Hover to view data
No Data
